Amphastar Pharmaceuticals, Inc. (AMPH) — SEC Filings

Latest SEC filings for Amphastar Pharmaceuticals, Inc. (AMPH), explained in plain English.

Sentiment Overview: 1 bearish, 28 neutral

Recent Filings (29)

• Amphastar's Q3 Net Income Plummets 57% Amid Soaring Expenses — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  Amphastar Pharmaceuticals, Inc. reported a significant decline in net income for the three and nine months ended September 30, 2025, despite a slight increase i
• Amphastar Pharmaceuticals Enters Material Definitive Agreement — 8-K · 2025-10-24T00:00:00.000Z [neutral] Risk: medium
  On October 21, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature of the agree
• Amphastar Pharmaceuticals Enters Material Definitive Agreement — 8-K · 2025-09-18T00:00:00.000Z [neutral] Risk: medium
  On September 15, 2025, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agre
• Amphastar Pharmaceuticals Enters Material Definitive Agreement — 8-K · 2025-08-12T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. announced on August 8, 2025, that it has entered into a Material Definitive Agreement. The filing also includes Regulation FD Di
• Amphastar Boosts Share Buybacks, Reports Steady Product Revenue — 10-Q · 2025-08-07T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed its 10-Q on August 7, 2025, for the quarter ended June 30, 2025. The company reported significant activity in its share re
• Amphastar Pharmaceuticals Announces Board and Compensation Changes — 8-K · 2025-07-21T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. announced on July 18, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the
• Amphastar Pharmaceuticals Files 8-K on Corporate Matters — 8-K · 2025-06-04T00:00:00.000Z [neutral] Risk: low
  On June 2, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, submission of matters to a
• Amphastar Pharmaceuticals Files 10-Q for Q1 2025 — 10-Q · 2025-05-08T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including common stock, retained e
• Amphastar Pharmaceuticals Files 8-K — 8-K · 2025-05-07T00:00:00.000Z [neutral] Risk: low
  On May 7, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Amphastar Pharma Files 2024 Proxy Statement — DEF 14A · 2025-04-14T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed its DEF 14A on April 14, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, in
• Amphastar Pharmaceuticals Files 2024 10-K — 10-K · 2025-03-03T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ending December 31, 2024. The filing details the company's finan
• Amphastar Pharmaceuticals Files 8-K on Financials — 8-K · 2025-02-27T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on February 27, 2025, reporting on its results of operations and financial condition, as well as filing financial s
• Amphastar Pharmaceuticals Files Q3 2024 10-Q — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and activities, inclu
• Amphastar Pharmaceuticals Files 8-K on Financials — 8-K · 2024-11-06T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on November 6, 2024, to report on its results of operations and financial condition, as well as to file financial s
• Amphastar Pharma Secures $150M Loan Facility — 8-K · 2024-08-30T00:00:00.000Z [neutral] Risk: medium
  On August 28, 2024, Amphastar Pharmaceuticals, Inc. entered into a material definitive agreement, specifically a Loan and Security Agreement with an affiliate o
• Amphastar Pharmaceuticals Q2 2024 10-Q Filing — 10-Q · 2024-08-09T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the sec
• Amphastar Pharmaceuticals Files 8-K on Financials — 8-K · 2024-08-07T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, to report on its results of operations and financial condition, and to file financial statements
• Amphastar Pharmaceuticals Appoints New CFO — 8-K · 2024-06-04T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. announced on June 3, 2024, the appointment of Robert J. Lerman as Chief Financial Officer, effective immediately. Lerman previou
• Amphastar Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-10T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. (AMPH) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Amphastar Pharmaceuticals, Inc. filed a 10-Q report for the
• Amphastar Pharmaceuticals Files 8-K — 8-K · 2024-05-08T00:00:00.000Z [neutral] Risk: low
  On May 8, 2024, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Amphastar Pharmaceuticals Files Definitive Proxy Statement — DEFA14A · 2024-04-19T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on April 19, 2024. This filing is related to the company's annual meeting and the s
• Amphastar Pharmaceuticals Files Definitive Proxy Statement — DEFA14A · 2024-04-12T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed a definitive proxy statement on April 12, 2024, for its annual meeting of stockholders. The filing indicates that Amphasta
• SC 13G/A Filing — SC 13G/A · 2024-03-06T00:00:00.000Z [neutral]
• Amphastar Pharmaceuticals, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-29T00:00:00.000Z [neutral] Risk: medium
  Amphastar Pharmaceuticals, Inc. (AMPH) filed a Annual Report (10-K) with the SEC on February 29, 2024. Amphastar Pharmaceuticals, Inc. filed its 10-K report for
• Amphastar Pharma Files 8-K on Financial Condition — 8-K · 2024-02-28T00:00:00.000Z [neutral] Risk: low
  Amphastar Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, to report on its results of operations and financial condition. The filing, under SEC File Nu
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Amphastar Insider Jack Zhang Updates Holdings; Maintains Significant Stake — SC 13G/A · 2024-02-09T00:00:00.000Z [neutral] Risk: low
  Jack Yongfeng Zhang, a key insider at Amphastar Pharmaceuticals, Inc., has filed an amendment (SC 13G/A) indicating a change in his beneficial ownership as of D
• BlackRock Amends Amphastar Pharma Stake (SC 13G/A) — SC 13G/A · 2024-01-23T00:00:00.000Z [neutral]
  BlackRock, Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership stake in Amphastar Pharmaceuticals, Inc. as of December 31,
• Federated Hermes Amends Amphastar Pharma Stake as of Dec 31, 2023 — SC 13G/A · 2024-01-17T00:00:00.000Z [neutral]
  Federated Hermes, Inc. filed an amended SC 13G/A on January 17, 2024, disclosing its ownership of Amphastar Pharmaceuticals, Inc. common stock as of December 31